Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.
about
Current concept in neural regeneration research: NSCs isolation, characterization and transplantation in various neurodegenerative diseases and stroke: A reviewEffects of five Ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson's disease model.Model-based dietary optimization for late-stage, levodopa-treated, Parkinson's disease patients.Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson's disease.Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication.Medication Therapy Management Service for Patients with Parkinson's Disease: A Before-and-After Study.Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.Context-sensitive network-based disease genetics prediction and its implications in drug discovery.Drugs for Parkinson’s disease: levodopa is still the gold standard.DYNAMIC PREDICTION FOR MULTIPLE REPEATED MEASURES AND EVENT TIME DATA: AN APPLICATION TO PARKINSON'S DISEASE.microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets.β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
P2860
Q26861926-16CF9728-4D66-43F0-A69A-03B21EC5A156Q30420129-B3C18318-6B05-4477-A470-297D59F19CE7Q33917819-684701A6-E3D1-432C-9E0D-C2B0839D59F5Q34395518-0D6D8B18-0037-43B7-915A-90DCA6FE7CA6Q36301580-986373D6-FFF3-44A5-9715-6AF90A5E352CQ37033702-9E1ABA6A-A114-433D-BD25-C22930A41231Q37233228-6ED26B43-D21F-43FB-B846-FC3C10360C00Q37790274-CB3B111F-17A3-48A7-AA13-2F41245B85C5Q37979869-C74E6E5E-4E9F-4C61-B3C5-D92958D960A1Q38179453-C839E8CA-5E48-4B21-8FEB-6C3FAC307926Q39010887-3F70B9B5-DB5C-45BA-BE8D-51A19438D717Q39035004-E1936C8E-8B20-40F5-AE73-16C6324D1996Q42392688-63C6838C-7501-4C90-8484-D582483697DEQ42976854-97723B7C-EE87-4248-A4E1-EFBA2FCF7276Q47564833-EDA78635-DAB8-4E15-8CF3-56E11FE22D19Q47754459-E67202E3-D3A7-485D-8492-815CEE4F60E8Q48453275-5E548255-38F4-4BA9-836B-4B3414DC8255Q48825282-DF588937-F449-4441-ACFB-FE1AE86DBDC1Q50483266-ADD562D0-3B3A-4E75-AD3E-D5ED0178529FQ50634271-3C55B220-D157-45A6-80DB-4FB25D5E1DA5Q55424330-B24FC74F-1B71-449D-9835-D48CFEA3B285
P2860
Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Optimizing levodopa therapy fo ...... nical and patient perspective.
@en
Optimizing levodopa therapy fo ...... nical and patient perspective.
@nl
type
label
Optimizing levodopa therapy fo ...... nical and patient perspective.
@en
Optimizing levodopa therapy fo ...... nical and patient perspective.
@nl
prefLabel
Optimizing levodopa therapy fo ...... nical and patient perspective.
@en
Optimizing levodopa therapy fo ...... nical and patient perspective.
@nl
P2860
P921
P356
P1476
Optimizing levodopa therapy fo ...... nical and patient perspective.
@en
P2093
David J Brooks
P2860
P356
10.2147/NDT.S1660
P407
P577
2008-02-01T00:00:00Z